ArticleEuropean journal of medical research2025
Unveiling the multifaceted role of the FLNC gene: implications for cancer diagnosis and prognosis.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Filamin C activates MAPK/ERK signaling to facilitate epithelial-mesenchymal transition in bladder cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Comprehensive analysis of programmed cell death and oridonin target identification in primary lung cancer for prognostic prediction and therapeutic strategies.Scientific reports · 2026Article
- A Comprehensive Analysis of Novel Variations Associated with Bile Duct Cancer: Insights into Expression, Methylation, and 3D Protein Structure.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundThe Filamin C (FLNC) gene, pivotal for cellular structure and function, holds significance in cancer biology.
methodsWe conducted a comprehensive study using various analytical approaches, including survival analysis, immune response assessment, methylation profiling, and single-cell analysis.
resultsOur findings indicate that abnormal FLNC expression correlates with unfavorable prognosis across multiple cancer types, suggesting its potential as a prognostic biomarker. FLNC dysfunction influences the tumor microenvironment, promoting immunosuppressive conditions and disease progression. Methylation profiling reveals a strong correlation between increased methylation, FLNC downregulation, and patient survival, highlighting the role of epigenetic regulation in cancer development. Single-cell analysis uncovers spatial and temporal variations in FLNC expression, identifying distinct cancer cell subsets with unique functional implications. Finally, immunohistochemistry was used to verify the results in different tumors.
conclusionsIn conclusion, our research provides insights into the versatile role of FLNC in cancer biology, emphasizing its clinical significance and potential applications as a diagnostic, prognostic, and therapeutic target across diverse cancer types. These findings offer valuable insights for personalized therapeutic interventions and precision medicine approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.